135701-67-6

Basic information

• Product Name: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG
• Synonyms: (D-ARG0,HYP3,D-PHE7,LEU8)-BRADYKININ;D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG;D-ARG-[HYP3,D-PHE7,LEU8]-BRADYKININ;H-D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG-OH;Aaphgpspla;bradykinin, Arg-Hyp(3)-Phe(7)-Leu(8)-;D-Arg-L-Arg-L-Pro-L-t4Hyp-Gly-L-Phe-L-Ser-D-Phe-L-Leu-L-Arg-OH;D-Arg-L-Arg-L-Pro-4-Hydroxy-L-Pro-Gly-L-Phe-L-Ser-D-Phe-L-Leu-L-Arg-OH
• CAS NO: 135701-67-6
• Molecular Formula: C57H89N19O13
• Molecular Weight: 1248.44
• Product Categories: Bradykinins;Peptides and Proteins;Peptides for Cell Biology
• Mol File: 135701-67-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.48g/cm³
• Refractive Index: 1.676
• Storage Temp.: −20°C
• PKA: 3.34±0.10(Predicted)
• CAS DataBase Reference: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(CAS DataBase Reference)
• NIST Chemistry Reference: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(135701-67-6)
• EPA Substance Registry System: D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG(135701-67-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 135701-67-6(Hazardous Substances Data)

Usage

General Description

The chemical "D-ARG-ARG-PRO-HYP-GLY-PHE-SER-D-PHE-LEU-ARG" is a peptide composed of amino acids arranged in a specific sequence. The peptide starts with two D-arginine (D-ARG) residues, followed by proline (PRO), hydroxyproline (HYP), glycine (GLY), phenylalanine (PHE), serine (SER), D-phenylalanine (D-PHE), leucine (LEU), and ends with arginine (ARG). This sequence of amino acids defines the chemical properties and potential biological activities of the peptide. Peptides like this one may have various functions in the body, such as serving as signaling molecules, enzyme inhibitors, or structural components. Further research and analysis are needed to fully understand the specific role and potential applications of this particular peptide.

InChI:InChI=1/C57H89N19O13/c1-32(2)25-40(48(82)72-38(19-11-23-67-57(63)64)53(87)89-54(88)44-20-12-24-76(44)52(86)37(18-10-22-66-56(61)62)71-46(80)36(58)17-9-21-65-55(59)60)73-50(84)42(27-34-15-7-4-8-16-34)74-51(85)43(31-77)75-49(83)41(26-33-13-5-3-6-14-33)70-45(79)30-69-47(81)39-28-35(78)29-68-39/h3-8,13-16,32,35-44,68,77-78H,9-12,17-31,58H2,1-2H3,(H,69,81)(H,70,79)(H,71,80)(H,72,82)(H,73,84)(H,74,85)(H,75,83)(H4,59,60,65)(H4,61,62,66)(H4,63,64,67)/t35-,36-,37+,38+,39+,40+,41+,42-,43+,44+/m1/s1

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 40350-83-2 (2S,4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 4530-20-5 BOC-glycine 
• 13836-37-8 Boc-Arg(Tos)-OH 

Relevant articles and documents

Design, Synthesis, and in Vitro Activity of Bis(succinimido)hexane Peptide Heterodimers with Combined B1 and B2 Antagonist Activity

We have developed a series of peptide heterodimers based on the B2 antagonist D-Arg0-3,D-Phe7,Leu8>-BK (1) and the B1 antagonist Lys0-8,des-Arg9>-BK